Trial Profile
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Incyte Corporation
- 18 Apr 2022 Results (as of 8 May 2020; n=60) assessing safety of ruxolitinib, data on serious adverse events (SAEs) reported among patients in the EAP were collected, published in the Bone Marrow Transplantation.
- 01 Dec 2021 Status changed from recruiting to completed.
- 08 Dec 2020 Results reporting safety data from patients with steroid-refractory chronic GVHD who received Ruxolitinib in this Incyte-sponsored US EAP, were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.